A Double-Blind, 3-Arm, Parallel Group, Placebo- and Ropinirole-Controlled Study for SPM 962 in Advanced Parkinson's Disease Patients With Concomitant Treatment of L-dopa
Phase of Trial: Phase III
Latest Information Update: 08 Sep 2017
At a glance
- Drugs Rotigotine (Primary) ; Ropinirole
- Indications Parkinson's disease
- Focus Registrational; Therapeutic Use
- Sponsors Otsuka Pharmaceutical
- 05 Jul 2012 New source identified and integrated (ClinicalTrials.gov: US National Institutes of Health NCT01628926).
- 04 Jul 2012 Additional trial centre, additional trial identifiers (NCT01628926, 243-08-001, JapicCTI090888), Inclusion and exclusion identified as reported by ClinicalTrials.gov.
- 29 Jun 2012 Actual end date (1 May 2011) added as reported by ClinicalTrials.gov.
Most Recent Events
Table of Contents
- At a glance
- Trial Overview
- Trial Details
- Trial Centres
- Trial History